05:16 PM EDT, 03/19/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) completed the sale of its Baltimore-Bayview drug substance manufacturing facility in Maryland to India's Syngene International for $36.5 million.

The sale covers the facility's assets and equipment, Emergent said Wednesday in a statement.

Emergent retains the option to access manufacturing services and capacity at the site to support future growth and pandemic response efforts in partnership with Syngene.